


Supplementary Figure S3



Supplementary Figure S3. *In situ* Flagrp170 immunotherapy does not induce tissue toxicities. Mice bearing B16 tumors of 4-5 mm sizes (n=5) received treatment with mouse version of Flagrp170 (mFlagrp170) or its human counterpart (hFlagrp170) for a total of five doses. Body weight of treated mice (A) and alanine aminotransferase (ALT) levels in the serum (B) were examined during the course of treatment. (C) Hearts, kidneys, livers or spleens from treated mice were subjected to histological analysis to examine potential adverse immune pathology (Bar = 10 μ m). Data shown are representative of three independent experiments. NS, not significant, using student t-test.